HRT Financial
MBRX icon

HRT Financial’s Moleculin Biotech MBRX Stock Holding History

HRT Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-687
Closed -$31K – 4884
2026
Q1 		$31K Buy
+687
New +$45.5K ﹤0.01% 3523
2025
Q4 		– Sell
-230
Closed -$61K – 3674
2025
Q3 		$61K Buy
+230
New +$62.1K ﹤0.01% 2579
2023
Q2 		– Sell
-2
Closed -$15K – 2929
2023
Q1 		$15K Buy
+2
New +$17.5K ﹤0.01% 2211
2021
Q1 		– Hold
0
– -$8K – 2960
2020
Q4 		– Hold
0
– – – 1764
2019
Q4 		– Hold
0
– -$22K – 1448
2019
Q3 		– Hold
0
– – – 1335

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HRT Financial's MBRX Position: Q2 2026 in Review

HRT Financial sold out of Moleculin Biotech (MBRX) in Q2 2026, closing a stake of 687 shares — an estimated $31K sold.

HRT Financial first reported a position in MBRX in Q1 2023 and held it in 3 quarters. The position peaked at $61K in Q3 2025. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • HRT Financial reported no remaining Moleculin Biotech position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 687 Moleculin Biotech shares in Q2 2026, an estimated $31K.
  • HRT Financial first reported a position in Moleculin Biotech in Q1 2023 and held it in 3 quarters.
  • HRT Financial's Moleculin Biotech position peaked at $61K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.